| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3576 | nc00094221 | M. tuberculosis Dihydrofolate Reductase Inhibitor |
|
| DCC3577 | Nc2213 | Novel inhibitor of methionine aminopeptidase 2 (MetAP2) |
|
| DCC3578 | Ncats-sm1440 | First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
| DCC3579 | Ncats-sm1441 | First-in-class, potent, and selective Lactate dehydrogenase inhibitor |
|
| DCC3580 | Ncb0970 | Less active trans-isomer of NCB-0846, acting as the negative control for NCB-0846, showing 13-fold weaker TNIK enzyme-inhibitory activity |
|
| DCC3581 | Ncdm-32 | Potent pan KDM Inhibitor, inhibiting KDM2A, KDM7A, KDM7B, KDM4A, KDM4C, and KDM5A |
|
| DCC3582 | Ncgc00117362 | Novel inhibitor of ovarian cancer metastasis, adhesion, invasion and proliferation |
|
| DCC3583 | Ncgc00120943 | Novel Agonist for Human Resolvin D1 Receptor DRV1 with Pro-Resolving Functions |
|
| DCC3584 | NCGC00161856 Featured | NCGC00161856 is identified as the first small-molecule ligand and inverse agonist of the thyroid-stimulating hormone receptor (TSHR). It inhibits basal cAMP production in HEK-EM 293 cells that stably express TSHRs, with a half-maximal inhibitory concentration (IC50) of 3.0 µM. This means that NCGC00161856 effectively reduces the constitutive activity of TSHR, which is the receptor's activity in the absence of its natural ligand (thyroid-stimulating hormone, TSH). |
|
| DCC3585 | ncgc00242595 | TSHR neutral antagonist, inhibiting stimulated signaling but not basal signaling |
|
| DCC3586 | Ncgc00249987 | Novel allosteric Eya2 phosphatase inhibitor, specifically targeting migration, invadopodia formation, and invasion of lung cancer cells |
|
| DCC3587 | Ncgc00262654 | Novel AMA1-RON2 Inhibitor |
|
| DCC3588 | Ncgc2327 | Novel potent inhibitor of IRAK1/4 and FLT3 |
|
| DCC3589 | Nco-04 | Novel SIRT1 inhibitor, inducing cell death in adult T-cell leukaemia cells |
|
| DCC3590 | Ncrw0005-f05 | Novel GPR139 receptor agonist |
|
| DCC3591 | Ncs-382 | Analogue of γ-hydroxybutyric acid (GHB), acting as a substrate for both the monocarboxylate transporter subtype 1 (MCT1) and subtype 4 (MCT4) |
|
| DCC3592 | Ncs-8591 | Beclin 1 mimetic, selectively binding to Bcl-xL and inducing autophagy, showing potent cytotoxicity in PC-3, PC-3a and DU145 prostate cancer cells |
|
| DCC3593 | Nctu-alan-2026 | Novel blocker of the interaction between FGF1 and FGFRD2 to inhibit cell proliferation, showing potent antiproliferent with less cytotoxicity. |
|
| DCC3594 | ncx-2057 | Novel NO-donor, suppressing inflammatory and nociceptive responses |
|
| DCC3595 | Ncx-6560 | Novel HMG-CoA reductase inhibitor and nitric oxide donor |
|
| DCC3596 | N-cyano-sch-12679 Bromide | Cyanogen Bromide adduct of (R)-SCH-12679, a D1 antagonist |
|
| DCC3597 | Levomepromazine Maleate | Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
|
| DCC3598 | Nd1-yl2 | Novel degrader of steroid receptor co-activator 1 (SRC-1) |
|
| DCC3599 | Nd-2110 | Novel potent and highly specific IRAK4 inhibitor |
|
| DCC3600 | Nd-322 Hydrochloride | Selective water-soluble gelatinase inhibitor |
|
| DCC3601 | Nd-364 | Potent and selective inhibitor for gelatinases, matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MPP9) |
|
| DCC3602 | nd7001 | Inhibitor of Phosphodiesterase (PDE)-2 |
|
| DCC3603 | N-demethyldiltiazem | Precursor for radiolabeled diltiazem |
|
| DCC3604 | N-desmethyl Loperamide | Major metabolite of loperamide, also used as the precusor for radiolabelled loperamide |
|
| DCC3605 | Ndi-10 | Novel G4-DNA ligand, promoting transcription in Gram-positive bacteria and repressing transcription in Gram-negatives |
|
